GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

Transgenomic and Fiuotecnica Renew Cardiovascular Disease Gene Panel Agreement

  • Transgenomic renewed a collaboration with Fiuotecnica  to produce and market a genetic panel assay to predict the risk of cardiovascular disease and heart attacks using Transgenomic's WAVE® System.

    Transgenomic will supply its WAVE System technology and related reagents to Fiuotecnica. Upon completion of the assay development, Fiuotecnica will retain rights to market the cardiovascular panel in Italy, while Transgenomic will obtain rights to market the assay in the rest of the world.

    "Fiuotecnica has evaluated other platforms, but we believe that Transgenomic's unique technology platforms, including the WAVE System for DHPLC analysis and Surveyor Nuclease, provide the highest sensitivity for mutation detection," states Antonio Mele, CEO of Fiuotecnica.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?